Patents by Inventor Young Gil Ahn

Young Gil Ahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240423979
    Abstract: This invention relates to pharmaceutical compositions, pharmaceutical combinations and methods for the treatment of acute myeloid leukemia by combined use of a therapeutically effective combination of a compound of Chemical Formula 1, or a pharmaceutically acceptable salt thereof, solvate thereof, stereoisomer thereof, tautomer thereof, or combination thereof, wherein Ea, Eb, Ec, Ed, Z?, X?, Q, and k are defined herein; and a Bcl-2 inhibitor, or a Bcl-2 inhibitor and a hypomethylating agent.
    Type: Application
    Filed: October 20, 2022
    Publication date: December 26, 2024
    Inventors: Ji Sook KIM, Jae Yul CHOI, Young Gil AHN
  • Publication number: 20240173329
    Abstract: Provided are methods for the use of belvarafenib to treat brain cancer including metastatic brain cancer carrying a BRAF mutation, a NRAS mutation, a KRAS mutation, or a combination thereof.
    Type: Application
    Filed: March 8, 2022
    Publication date: May 30, 2024
    Inventors: Joanne Adamkewicz, Michael John Dolton, Shiva Malek, Piia Thomas, Jennifer Eng-Wong, Yibing Yan, Young Hoon KIM, Young Gil AHN, Yu Yon KIM
  • Publication number: 20240067613
    Abstract: A novel quinazoline compound having SOS1 inhibitory activity and uses of the quinazoline compound are disclosed. More particularly, the present invention relates to a novel quinazoline derivative compound having inhibitory activity on SOS1 binding to RAS family proteins and/or RAC1, to pharmacologically acceptable salts thereof, and to pharmaceutical compositions containing the quinazoline compound. The novel quinazoline compound has the following chemical formula 1: wherein all the variables have meaning as defined in the specification.
    Type: Application
    Filed: December 14, 2021
    Publication date: February 29, 2024
    Applicant: HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jae Yul CHOI, Won Jeoung KIM, Ji Sook KIM, Min Jeong KIM, Won Gi PARK, Young Gil AHN, In Hwan BAE
  • Patent number: 11649246
    Abstract: The present invention relates to a crystalline form of a salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and a pharmaceutical composition containing the same. The crystalline form of the salt of the compound can be easily used for preparing a pharmaceutical composition containing the same as an active ingredient.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: May 16, 2023
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: Chang Hee Park, Seung Hyun Jung, Young Gil Ahn, Kwee Hyun Suh
  • Publication number: 20230060973
    Abstract: The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.
    Type: Application
    Filed: October 6, 2022
    Publication date: March 2, 2023
    Inventors: In Hwan BAE, Seung Hyun JUNG, Young Gil AHN, Kwee Hyun SUH
  • Publication number: 20230002358
    Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.
    Type: Application
    Filed: January 25, 2022
    Publication date: January 5, 2023
    Inventors: In Hwan BAE, Ji Sook KIM, Jae Yul CHOI, Seok Jong KANG, Young Gil AHN, Kwee Hyun SUH
  • Patent number: 11535629
    Abstract: Disclosed are novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts thereof, optical isomers, hydrates, and solvates thereof as well as uses thereof. More specifically, the novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts, optical isomers, hydrates, solvates show inhibition activity of EZH1 (Enhancer of zeste homolog 1) and/or EZH2 (Enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing the compound is also disclosed.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: December 27, 2022
    Assignee: HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Seung Hyun Jung, Dong Jin Hong, Ji Young Hwang, Seo Hee Kim, So Min Park, Shin Mee Mah, Young Gil Ahn
  • Publication number: 20220354842
    Abstract: Provided are: a pharmaceutical composition for treating myeloid leukemia (AML), and a method for treating acute myeloid leukemia using same, the pharmaceutical composition comprising a therapeutically effective combination of an Fms-like tyrosine kinase-3 (FLT3) inhibitor or pharmaceutically acceptable salt or solvate thereof, and a chemotherapeutic agent or pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: June 25, 2020
    Publication date: November 10, 2022
    Inventors: In Hwan BAE, Ji Young SONG, Jae Yul CHOI, Young Gil AHN
  • Patent number: 11492357
    Abstract: The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: November 8, 2022
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: In Hwan Bae, Seung Hyun Jung, Young Gil Ahn, Kwee Hyun Suh
  • Publication number: 20220275000
    Abstract: Disclosed are novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts thereof, optical isomers, hydrates, and solvates thereof as well as uses thereof. More specifically, the novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts, optical isomers, hydrates, solvates show inhibition activity of EZH1 (Enhancer of zeste homolog 1) and/or EZH2 (Enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing the compound is also disclosed.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 1, 2022
    Applicant: HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Seung Hyun JUNG, Dong Jin HONG, Ji Young HWANG, Seo Hee KIM, So Min PARK, Shin Mee MAH, Young Gil AHN
  • Publication number: 20220135582
    Abstract: A novel heterotricyclic compounds of Formula 1 or pharmaceutically acceptable salts thereof, and uses thereof are disclosed. The novel heterotricyclic compounds exhibit an inhibitory activity against EZH1 (enhancer of zeste homolog 1) and/or EZH2 (enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing these compounds as active ingredient is also disclosed. The heterotricyclic compound, pharmaceutically acceptable salts thereof, or compositions containing the compound or salt are useful in treating tumor or cancer in a subject.
    Type: Application
    Filed: February 19, 2020
    Publication date: May 5, 2022
    Applicant: HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Dong Jin HONG, Seung Hyun JUNG, Chang Hee PARK, Seo Hee KIM, Ji Young HWANG, Young Gil AHN
  • Publication number: 20220110913
    Abstract: Provided are a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition containing an Fms-like tyrosine kinase (Fms-like tyrosine kinase-3: FLT3) inhibitor or a pharmaceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA) or a pharmaceutically acceptable salt or solvate thereof in a therapeutically effective combination, and a method of treating AML using the composition.
    Type: Application
    Filed: February 21, 2020
    Publication date: April 14, 2022
    Applicant: HANMI PHARM. CO., LTD
    Inventors: In Hwan BAE, Ji Sook KIM, JaeYul CHOI, Young Gil AHN
  • Patent number: 11292786
    Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: April 5, 2022
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: In Hwan Bae, Ji Sook Kim, Jae Yul Choi, Seok Jong Kang, Young Gil Ahn, Kwee Hyun Suh
  • Publication number: 20220098205
    Abstract: Provided is a compound selected from a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically acceptable salts of the aforementioned components. The compound is effective in the prevention or treatment of diseases caused by abnormal activation of LSD1. Also disclosed is a composition containing the compound as an active ingredient and its uses in preventing and/or treating diseases caused by abnormal activation of LSD1.
    Type: Application
    Filed: January 31, 2020
    Publication date: March 31, 2022
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: In Hwan BAE, Won Jeoung KIM, Ji Sook KIM, Ji Young SONG, Jae Yul CHOI, Min Jeong KIM, Jung Soo NAM, Young Gil AHN
  • Patent number: 11254676
    Abstract: Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 22, 2022
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: In Hwan Bae, Ji Sook Kim, Won Jeoung Kim, Chang Hee Park, Ji Young Song, Young Gil Ahn
  • Publication number: 20210009591
    Abstract: Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 14, 2021
    Applicant: Hanmi Pharm. Co., Ltd.
    Inventors: In Hwan BAE, Ji Sook KIM, Won Jeoung KIM, Chang Hee PARK, Ji Young SONG, Young Gil AHN
  • Patent number: 10870639
    Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: December 22, 2020
    Assignee: HANMI PHARM. CO.. LTD.
    Inventors: In Hwan Bae, Ji Sook Kim, Jae Yul Choi, Seok Jong Kang, Young Gil Ahn, Kwee Hyun Suh
  • Publication number: 20200308187
    Abstract: The present invention relates to a crystalline form of a salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and a pharmaceutical composition containing the same. The crystalline form of the salt of the compound can be easily used for preparing a pharmaceutical composition containing the same as an active ingredient.
    Type: Application
    Filed: November 29, 2018
    Publication date: October 1, 2020
    Inventors: Chang Hee PARK, Seung Hyun JUNG, Young Gil AHN, Kwee Hyun SUH
  • Publication number: 20200308188
    Abstract: The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.
    Type: Application
    Filed: November 29, 2018
    Publication date: October 1, 2020
    Inventors: In Hwan BAE, Seung Hyun JUNG, Young Gil AHN, Kwee Hyun SUH
  • Publication number: 20200255410
    Abstract: Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: In Hwan BAE, Ji Sook KIM, Jae Yul CHOI, Seok Jong KANG, Young Gil AHN, Kwee Hyun SUH